APO Research
Talk to an analyst

APO RESEARCH · REPORT

CXCR4 Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global CXCR4 Antagonists Industry Growth and Trends Forecast to 2032

20 December 2025102 pages

Choose your research edition.

Industry ResearchCXCR4 Antagonists Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CXCR4 Antagonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal CXCR4 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CXCR4 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal CXCR4 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

According to APO Research, the global CXCR4 Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the CXCR4 Antagonists market include Sanofi, Merck, Roche, Eli Lilly, X4 Pharmaceuticals, Upsher-Smith Laboratories, Harmonic Pharma, GlycoMimetics and BioLineRx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global CXCR4 Antagonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The CXCR4 Antagonists market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CXCR4 Antagonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CXCR4 Antagonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global CXCR4 Antagonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

CXCR4 Antagonists Market by Company

Sanofi

Merck

Roche

Eli Lilly

X4 Pharmaceuticals

Upsher-Smith Laboratories

Harmonic Pharma

GlycoMimetics

BioLineRx

Biokine Therapeutics

CXCR4 Antagonists Segment by Type

USL311

Balixafortide (POL6326)

GMI-1359

BL-8040

Plerixafor (AMD3100)

Others

CXCR4 Antagonists Segment by Application

Chronic Inflammatory Diseases

HIV

Cancer

CXCR4 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CXCR4 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CXCR4 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CXCR4 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of CXCR4 Antagonists companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global CXCR4 Antagonists Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global CXCR4 Antagonists Market Size by Region (2021-2026) & (US$ Million) Table 3. Global CXCR4 Antagonists Market Share by Region (2021-2026) Table 4. Global CXCR4 Antagonists Market Size by Region (2027-2032) & (US$ Million) Table 5. Global CXCR4 Antagonists Market Share by Region (2027-2032) Table 6. Global CXCR4 Antagonists Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global CXCR4 Antagonists Market Size by Type (2021-2026) & (US$ Million) Table 8. Global CXCR4 Antagonists Market Size Share by Type (2021-2026) Table 9. Global CXCR4 Antagonists Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global CXCR4 Antagonists Market Size Share Forecasted by Type (2027-2032) Table 11. North America CXCR4 Antagonists Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America CXCR4 Antagonists Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe CXCR4 Antagonists Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe CXCR4 Antagonists Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America CXCR4 Antagonists Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America CXCR4 Antagonists Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global CXCR4 Antagonists Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global CXCR4 Antagonists Market Size by Application (2021-2026) & (US$ Million) Table 23. Global CXCR4 Antagonists Market Size Share by Application (2021-2026) Table 24. Global CXCR4 Antagonists Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global CXCR4 Antagonists Market Size Share Forecasted by Application (2027-2032) Table 26. North America CXCR4 Antagonists Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America CXCR4 Antagonists Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe CXCR4 Antagonists Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe CXCR4 Antagonists Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America CXCR4 Antagonists Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America CXCR4 Antagonists Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. CXCR4 Antagonists Industry Trends Table 37. CXCR4 Antagonists Industry Drivers Table 38. CXCR4 Antagonists Industry Opportunities and Challenges Table 39. CXCR4 Antagonists Industry Restraints Table 40. Global CXCR4 Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 41. Global CXCR4 Antagonists Revenue Market Share by Company (2021-2026) Table 42. Global CXCR4 Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global CXCR4 Antagonists Key Company Headquarters & Area Served Table 44. Global CXCR4 Antagonists Company, Product Type & Application Table 45. Global CXCR4 Antagonists Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global CXCR4 Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sanofi CXCR4 Antagonists Product Portfolio Table 52. Sanofi Recent Development Table 53. Merck Company Information Table 54. Merck Business Overview Table 55. Merck CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Merck CXCR4 Antagonists Product Portfolio Table 57. Merck Recent Development Table 58. Roche Company Information Table 59. Roche Business Overview Table 60. Roche CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Roche CXCR4 Antagonists Product Portfolio Table 62. Roche Recent Development Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Eli Lilly CXCR4 Antagonists Product Portfolio Table 67. Eli Lilly Recent Development Table 68. X4 Pharmaceuticals Company Information Table 69. X4 Pharmaceuticals Business Overview Table 70. X4 Pharmaceuticals CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio Table 72. X4 Pharmaceuticals Recent Development Table 73. Upsher-Smith Laboratories Company Information Table 74. Upsher-Smith Laboratories Business Overview Table 75. Upsher-Smith Laboratories CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio Table 77. Upsher-Smith Laboratories Recent Development Table 78. Harmonic Pharma Company Information Table 79. Harmonic Pharma Business Overview Table 80. Harmonic Pharma CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Harmonic Pharma CXCR4 Antagonists Product Portfolio Table 82. Harmonic Pharma Recent Development Table 83. GlycoMimetics Company Information Table 84. GlycoMimetics Business Overview Table 85. GlycoMimetics CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. GlycoMimetics CXCR4 Antagonists Product Portfolio Table 87. GlycoMimetics Recent Development Table 88. BioLineRx Company Information Table 89. BioLineRx Business Overview Table 90. BioLineRx CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. BioLineRx CXCR4 Antagonists Product Portfolio Table 92. BioLineRx Recent Development Table 93. Biokine Therapeutics Company Information Table 94. Biokine Therapeutics Business Overview Table 95. Biokine Therapeutics CXCR4 Antagonists Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Biokine Therapeutics CXCR4 Antagonists Product Portfolio Table 97. Biokine Therapeutics Recent Development Table 98. North America CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America CXCR4 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 100. North America CXCR4 Antagonists Market Share by Country (2021-2026) Table 101. North America CXCR4 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America CXCR4 Antagonists Market Share Forecast by Country (2027-2032) Table 103. Europe CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Europe CXCR4 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 105. Europe CXCR4 Antagonists Market Share by Country (2021-2026) Table 106. Europe CXCR4 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Europe CXCR4 Antagonists Market Share Forecast by Country (2027-2032) Table 108. Asia-Pacific CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Asia-Pacific CXCR4 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 110. Asia-Pacific CXCR4 Antagonists Market Share by Country (2021-2026) Table 111. Asia-Pacific CXCR4 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Asia-Pacific CXCR4 Antagonists Market Share Forecast by Country (2027-2032) Table 113. Latin America CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Latin America CXCR4 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 115. Latin America CXCR4 Antagonists Market Share by Country (2021-2026) Table 116. Latin America CXCR4 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Latin America CXCR4 Antagonists Market Share Forecast by Country (2027-2032) Table 118. Middle East & Africa CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Middle East & Africa CXCR4 Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 120. Middle East & Africa CXCR4 Antagonists Market Share by Country (2021-2026) Table 121. Middle East & Africa CXCR4 Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Middle East & Africa CXCR4 Antagonists Market Share Forecast by Country (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. CXCR4 Antagonists Product Image Figure 3. Global CXCR4 Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global CXCR4 Antagonists Market Size (2021-2032) & (US$ Million) Figure 5. Global CXCR4 Antagonists Market Share by Region: 2025 VS 2032 Figure 6. Global CXCR4 Antagonists Market Share by Region (2021-2032) Figure 7. North America CXCR4 Antagonists Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe CXCR4 Antagonists Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific CXCR4 Antagonists Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America CXCR4 Antagonists Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa CXCR4 Antagonists Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. USL311 Image Figure 13. Global USL311 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Balixafortide (POL6326) Image Figure 15. Global Balixafortide (POL6326) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. GMI-1359 Image Figure 17. Global GMI-1359 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. BL-8040 Image Figure 19. Global BL-8040 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Plerixafor (AMD3100) Image Figure 21. Global Plerixafor (AMD3100) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Others Image Figure 23. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global CXCR4 Antagonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global CXCR4 Antagonists Market Share by Type 2025 VS 2032 Figure 26. North America CXCR4 Antagonists Market Size Share by Type (2021-2032) Figure 27. Europe CXCR4 Antagonists Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific CXCR4 Antagonists Market Size Share by Type (2021-2032) Figure 29. Latin America CXCR4 Antagonists Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa CXCR4 Antagonists Market Size Share by Type (2021-2032) Figure 31. Chronic Inflammatory Diseases Image Figure 32. Global Chronic Inflammatory Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. HIV Image Figure 34. Global HIV Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Cancer Image Figure 36. Global Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global CXCR4 Antagonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global CXCR4 Antagonists Market Share by Application 2025 VS 2032 Figure 39. North America CXCR4 Antagonists Market Size Share by Application (2021-2032) Figure 40. Europe CXCR4 Antagonists Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific CXCR4 Antagonists Market Size Share by Application (2021-2032) Figure 42. Latin America CXCR4 Antagonists Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa CXCR4 Antagonists Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 CXCR4 Antagonists Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America CXCR4 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America CXCR4 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America CXCR4 Antagonists Market Share by Country (2021-2032) Figure 49. Europe CXCR4 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe CXCR4 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe CXCR4 Antagonists Market Share by Country (2021-2032) Figure 52. Asia-Pacific CXCR4 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific CXCR4 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific CXCR4 Antagonists Market Share by Country (2021-2032) Figure 55. Latin America CXCR4 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America CXCR4 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America CXCR4 Antagonists Market Share by Country (2021-2032) Figure 58. Middle East & Africa CXCR4 Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa CXCR4 Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa CXCR4 Antagonists Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • USL311
  • Balixafortide (POL6326)
  • GMI-1359
  • BL-8040
  • Plerixafor (AMD3100)
  • Others
Applications
  • Chronic Inflammatory Diseases
  • HIV
  • Cancer
Companies covered
  • Sanofi
  • Merck
  • Roche
  • Eli Lilly
  • X4 Pharmaceuticals
  • Upsher-Smith Laboratories
  • Harmonic Pharma
  • GlycoMimetics
  • BioLineRx
  • Biokine Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global CXCR4 Antagonists Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global CXCR4 Antagonists Market Size by Region (2021-2032)
  5. 1.4.1 Global CXCR4 Antagonists Market Size by Region (2021-2026)
  6. 1.4.2 Global CXCR4 Antagonists Market Size by Region (2027-2032)
  7. 1.5 Key Regions CXCR4 Antagonists Market Size (2021-2032)
  8. 1.5.1 North America CXCR4 Antagonists Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe CXCR4 Antagonists Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific CXCR4 Antagonists Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America CXCR4 Antagonists Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa CXCR4 Antagonists Market Size Growth Rate (2021-2032)
2 CXCR4 Antagonists Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 USL311
  3. 2.1.2 Balixafortide (POL6326)
  4. 2.1.3 GMI-1359
  5. 2.1.4 BL-8040
  6. 2.1.5 Plerixafor (AMD3100)
  7. 2.1.6 Others
  8. 2.2 Global CXCR4 Antagonists Market Size by Type
  9. 2.2.1 Global CXCR4 Antagonists Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global CXCR4 Antagonists Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global CXCR4 Antagonists Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global CXCR4 Antagonists Market Size by Regions
  13. 2.3.1 North America CXCR4 Antagonists Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe CXCR4 Antagonists Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America CXCR4 Antagonists Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Type (2021-2026)
3 CXCR4 Antagonists Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Chronic Inflammatory Diseases
  3. 3.1.2 HIV
  4. 3.1.3 Cancer
  5. 3.2 Global CXCR4 Antagonists Market Size by Application
  6. 3.2.1 Global CXCR4 Antagonists Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global CXCR4 Antagonists Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global CXCR4 Antagonists Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global CXCR4 Antagonists Market Size by Regions
  10. 3.3.1 North America CXCR4 Antagonists Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe CXCR4 Antagonists Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific CXCR4 Antagonists Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America CXCR4 Antagonists Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa CXCR4 Antagonists Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 CXCR4 Antagonists Industry Trends
  2. 4.2 CXCR4 Antagonists Industry Drivers
  3. 4.3 CXCR4 Antagonists Industry Opportunities and Challenges
  4. 4.4 CXCR4 Antagonists Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by CXCR4 Antagonists Revenue (2021-2026)
  2. 5.2 Global CXCR4 Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global CXCR4 Antagonists Key Company Headquarters & Area Served
  4. 5.4 Global CXCR4 Antagonists Company, Product Type & Application
  5. 5.5 Global CXCR4 Antagonists Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global CXCR4 Antagonists Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 CXCR4 Antagonists Players Market Share by Revenue in 2025
  9. 5.6.3 2025 CXCR4 Antagonists Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi CXCR4 Antagonists Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Merck CXCR4 Antagonists Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Roche CXCR4 Antagonists Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly CXCR4 Antagonists Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 X4 Pharmaceuticals
  26. 6.5.1 X4 Pharmaceuticals Company Information
  27. 6.5.2 X4 Pharmaceuticals Business Overview
  28. 6.5.3 X4 Pharmaceuticals CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio
  30. 6.5.5 X4 Pharmaceuticals Recent Developments
  31. 6.6 Upsher-Smith Laboratories
  32. 6.6.1 Upsher-Smith Laboratories Company Information
  33. 6.6.2 Upsher-Smith Laboratories Business Overview
  34. 6.6.3 Upsher-Smith Laboratories CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio
  36. 6.6.5 Upsher-Smith Laboratories Recent Developments
  37. 6.7 Harmonic Pharma
  38. 6.7.1 Harmonic Pharma Company Information
  39. 6.7.2 Harmonic Pharma Business Overview
  40. 6.7.3 Harmonic Pharma CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Harmonic Pharma CXCR4 Antagonists Product Portfolio
  42. 6.7.5 Harmonic Pharma Recent Developments
  43. 6.8 GlycoMimetics
  44. 6.8.1 GlycoMimetics Company Information
  45. 6.8.2 GlycoMimetics Business Overview
  46. 6.8.3 GlycoMimetics CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 GlycoMimetics CXCR4 Antagonists Product Portfolio
  48. 6.8.5 GlycoMimetics Recent Developments
  49. 6.9 BioLineRx
  50. 6.9.1 BioLineRx Company Information
  51. 6.9.2 BioLineRx Business Overview
  52. 6.9.3 BioLineRx CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 BioLineRx CXCR4 Antagonists Product Portfolio
  54. 6.9.5 BioLineRx Recent Developments
  55. 6.10 Biokine Therapeutics
  56. 6.10.1 Biokine Therapeutics Company Information
  57. 6.10.2 Biokine Therapeutics Business Overview
  58. 6.10.3 Biokine Therapeutics CXCR4 Antagonists Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Biokine Therapeutics CXCR4 Antagonists Product Portfolio
  60. 6.10.5 Biokine Therapeutics Recent Developments
7 North America
  1. 7.1 North America CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America CXCR4 Antagonists Market Size by Country (2021-2026)
  3. 7.3 North America CXCR4 Antagonists Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe CXCR4 Antagonists Market Size by Country (2021-2026)
  3. 8.3 Europe CXCR4 Antagonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific CXCR4 Antagonists Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific CXCR4 Antagonists Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America CXCR4 Antagonists Market Size by Country (2021-2026)
  3. 10.3 South America CXCR4 Antagonists Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa CXCR4 Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa CXCR4 Antagonists Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa CXCR4 Antagonists Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst